Guided Therapeutics Inc. reported unaudited consolidated results for the first quarter ended March 31, 2014. Revenue and other income for the first quarter ended March 31, 2014 was approximately $141,000, including approximately $122,000 in sales of LuViva(R) devices and disposables, NIH grants totaling approximately $13,000, as well as other income from royalties of approximately $5,000. The net loss attributable to common stockholders for the first quarter of 2014 was approximately $1.6 million, or $0.02 per basic and diluted share, compared to approximately $1.8 million, or $0.03 per basic and diluted share, in the comparable quarter of 2013. Operating loss was $2,079,000 against $1,875,000 a year ago.

The company believes it is on track to report product sales of $1 million to $3 million for 2014, in line with previous revenue guidance.